Eye drug maker VivaVision feels the strain in IPO funding dash
The developer of new treatments for ocular disorders is in a race against time to secure a Hong Kong listing before its cash reserves run out Key Takeaways: Two VivaVision…
Flagship of China’s ‘Godfather of Cardiovascular Surgery’ Slices Towards IPO
The maker of cardiovascular interventional medical devices has been approved for a listing on the Hong Kong Stock ExchangeKey Takeaways:OrbusNeich Medical has been approved for a Hong Kong IPO, and…
